A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
ConditionAdvanced Malignant Solid Tumors
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorAkeso
About this trial
This study is an open-label, multicenter, dose-escalation and dose-expansion Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of AK150 in patients with advanced malignant solid tumors.
Eligibility criteria
Qualifiers
Be able to understand and voluntarily sign the written informed consent form.
Aged of ≥ 18 years and ≤75 years.
ECOG PS 0 or 1.
The expected lifespan is ≥3 months.
Disqualifiers
Having other active malignancies within 3 years.
Currently participating in another interventional clinical study.
Presence of active metastases to the central nervous system. For participants with asymptomatic brain metastasis or stable symptoms after treatment can be included.
Having received any treatment targeting CSF-1R, ILT2 and ILT4..
Trial design
Treatments tested in this trial
- AK150
Treatment groups
96 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov